The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Glucose-driven histone lactylation promotes immunosuppressive activity in glioblastoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Wistar Institute assistant professor Filippo Veglia and team have discovered a key mechanism of how glioblastoma suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Wistar’s Nan Zhang and Noam Auslander receive $1.2M in biomedical research grants from V Foundation

Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
Funding Opportunities

DOD Glioblastoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
Clinical Roundup

Wistar Institute researchers identify the role of a Parkinson’s disease-related protein in cancer and T-cell activation

The Wistar Institute’s president and CEO, Dario C. Altieri, and his team have demonstrated the role of Parkin—a protein implicated in Parkinson’s disease—in the body’s innate immune response to cancer. Parkin is not expressed in several cancers. Altieri and his team engineered cancer cells to re-express Parkin and found that Parkin contributes to the production of interferons, which activate and attract T cells to fight the tumor. The lab’s findings were published in The Journal of Clinical Investigation.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account